EA201692105A1 - Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1 - Google Patents

Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1

Info

Publication number
EA201692105A1
EA201692105A1 EA201692105A EA201692105A EA201692105A1 EA 201692105 A1 EA201692105 A1 EA 201692105A1 EA 201692105 A EA201692105 A EA 201692105A EA 201692105 A EA201692105 A EA 201692105A EA 201692105 A1 EA201692105 A1 EA 201692105A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazolopyrimidine derivatives
application
malt1
new pyrazolopyrimidine
new
Prior art date
Application number
EA201692105A
Other languages
English (en)
Other versions
EA032050B1 (ru
Inventor
Кароль Писсо Солдерманн
Жан Канкар
Ахим Шлапбах
Оливер Зимиц
Марина Тинтельнот-Бломлей
Томас Цоллер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201692105A1 publication Critical patent/EA201692105A1/ru
Publication of EA032050B1 publication Critical patent/EA032050B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Abstract

Настоящее изобретение описывает новые пиразолопиримидиновые производные, которые в целом взаимодействуют с MALT1 протеолитической и/или автопротеолитической активностью и, в частности, которые могут ингибировать указанную активность. Кроме того, настоящее изобретение описывает получение указанных новых пиразолопиримидиновых производных, их применение в качестве лекарственного средства, особенно взаимодействием с MALT1 протеолитической и/или автопротеолитической активностью.
EA201692105A 2014-05-28 2015-05-27 Пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1 EA032050B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170408 2014-05-28
PCT/IB2015/053975 WO2015181747A1 (en) 2014-05-28 2015-05-27 Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors

Publications (2)

Publication Number Publication Date
EA201692105A1 true EA201692105A1 (ru) 2017-04-28
EA032050B1 EA032050B1 (ru) 2019-03-29

Family

ID=50828759

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692105A EA032050B1 (ru) 2014-05-28 2015-05-27 Пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1

Country Status (36)

Country Link
US (2) US9815842B2 (ru)
EP (1) EP3149001B1 (ru)
JP (1) JP6545197B2 (ru)
KR (1) KR20170007311A (ru)
CN (1) CN106170489B (ru)
AP (1) AP2016009487A0 (ru)
AR (1) AR100645A1 (ru)
AU (1) AU2015265478B2 (ru)
BR (1) BR112016024545A2 (ru)
CA (1) CA2945077A1 (ru)
CL (1) CL2016002942A1 (ru)
CR (1) CR20160548A (ru)
CU (1) CU24393B1 (ru)
CY (1) CY1121946T1 (ru)
DK (1) DK3149001T3 (ru)
EA (1) EA032050B1 (ru)
ES (1) ES2738695T3 (ru)
GT (1) GT201600249A (ru)
HR (1) HRP20191261T1 (ru)
HU (1) HUE044351T2 (ru)
IL (1) IL247949A0 (ru)
LT (1) LT3149001T (ru)
MX (1) MX2016015544A (ru)
MY (1) MY182487A (ru)
PE (1) PE20170189A1 (ru)
PH (1) PH12016501862B1 (ru)
PL (1) PL3149001T3 (ru)
PT (1) PT3149001T (ru)
RS (1) RS59039B1 (ru)
SG (1) SG11201607895PA (ru)
SI (1) SI3149001T1 (ru)
SV (1) SV2016005328A (ru)
TR (1) TR201910730T4 (ru)
TW (1) TWI709561B (ru)
UY (1) UY36143A (ru)
WO (1) WO2015181747A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2808435C2 (ru) * 2018-11-28 2023-11-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
CA3003820A1 (en) * 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107296807B (zh) * 2016-04-15 2020-03-20 中国科学院上海生命科学研究院 Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
US20190275012A9 (en) 2016-07-29 2019-09-12 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
US10662156B2 (en) 2016-07-29 2020-05-26 Toray Industries, Inc. Guanidine derivative and medical use thereof
EP3490995A1 (en) 2016-07-29 2019-06-05 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3535254A4 (en) 2016-11-01 2020-06-24 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") COMPOUNDS FOR THE DEGRADATION OF MALT1
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3564227B1 (en) 2016-12-27 2022-02-23 Kao Corporation Method for producing glyceric acid ester derivatives
CN109415334B (zh) 2016-12-27 2023-12-08 花王株式会社 1,3-二噁烷-5-酮类的制造方法
US10822329B2 (en) 2016-12-27 2020-11-03 Kao Corporation Method for producing glyceric acid ester
WO2018141749A1 (en) 2017-02-01 2018-08-09 Medivir Ab Therapeutic applications of malt1 inhibitors
JPWO2018159650A1 (ja) * 2017-02-28 2019-12-19 東レ株式会社 グアニジン誘導体及びその医薬用途
JP7142022B2 (ja) * 2017-03-08 2022-09-26 コーネル・ユニバーシティー Ｍａｌｔ１の阻害剤およびそれらの使用
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
JP7157738B2 (ja) * 2017-06-08 2022-10-20 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
JP7271540B2 (ja) * 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Ａｓｋ１阻害剤としての尿素誘導体
CN112585128B (zh) 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
KR20210024002A (ko) * 2018-06-18 2021-03-04 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
TWI784213B (zh) 2018-11-28 2022-11-21 日商武田藥品工業股份有限公司 雜環化合物
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
CA3131856A1 (en) 2019-04-11 2020-10-15 Janssen Pharmaceutica N.V. Pyridine rings containing derivatives as malt1 inhibitors
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
CN111138437B (zh) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
EP4163280A1 (en) * 2020-05-27 2023-04-12 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
TW202220992A (zh) * 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2023139479A1 (en) * 2022-01-18 2023-07-27 Aurigene Oncology Limited Substituted bicyclic heterocycles as malt-1 inhibitors
TW202340198A (zh) * 2022-01-28 2023-10-16 大陸商上海齊魯製藥研究中心有限公司 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
ES2304511T3 (es) 2002-06-04 2008-10-16 Schering Corporation Compuestos de pirazolo(1,5-a)pirimidina como agentes antivirales.
EP1545533A1 (en) * 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
RU2402544C2 (ru) * 2005-01-14 2010-10-27 Си Джи Ай ФАРМАСЬЮТИКАЛЗ, ИНК. 1,3-диарилзамещенные мочевины как модуляторы киназной активности
AU2007321924A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
EP2222326B2 (en) * 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL2509602T3 (pl) * 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
US9822118B2 (en) * 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2808435C2 (ru) * 2018-11-28 2023-11-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение

Also Published As

Publication number Publication date
TR201910730T4 (tr) 2019-08-21
TWI709561B (zh) 2020-11-11
AU2015265478B2 (en) 2017-09-14
SI3149001T1 (sl) 2019-08-30
GT201600249A (es) 2018-12-18
PL3149001T3 (pl) 2019-10-31
US20180030061A1 (en) 2018-02-01
EP3149001B1 (en) 2019-04-24
EP3149001A1 (en) 2017-04-05
MY182487A (en) 2021-01-25
PH12016501862A1 (en) 2016-12-19
CN106170489B (zh) 2019-05-03
JP2017516778A (ja) 2017-06-22
HRP20191261T1 (hr) 2019-10-04
BR112016024545A2 (pt) 2017-08-15
RS59039B1 (sr) 2019-08-30
AU2015265478A1 (en) 2016-10-20
CR20160548A (es) 2017-01-02
IL247949A0 (en) 2016-11-30
MX2016015544A (es) 2017-03-23
US10442808B2 (en) 2019-10-15
WO2015181747A1 (en) 2015-12-03
KR20170007311A (ko) 2017-01-18
CA2945077A1 (en) 2015-12-03
AP2016009487A0 (en) 2016-10-31
US9815842B2 (en) 2017-11-14
CL2016002942A1 (es) 2017-07-14
CN106170489A (zh) 2016-11-30
EA032050B1 (ru) 2019-03-29
ES2738695T3 (es) 2020-01-24
SG11201607895PA (en) 2016-12-29
PH12016501862B1 (en) 2016-12-19
US20170121335A1 (en) 2017-05-04
AR100645A1 (es) 2016-10-19
CU20160181A7 (es) 2017-05-10
CY1121946T1 (el) 2020-10-14
SV2016005328A (es) 2018-06-12
JP6545197B2 (ja) 2019-07-17
HUE044351T2 (hu) 2019-10-28
DK3149001T3 (da) 2019-07-22
LT3149001T (lt) 2019-08-12
TW201609740A (zh) 2016-03-16
PT3149001T (pt) 2019-07-25
UY36143A (es) 2016-01-08
PE20170189A1 (es) 2017-03-15
CU24393B1 (es) 2019-04-04

Similar Documents

Publication Publication Date Title
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
PH12018500932A1 (en) Novel pyrazolo pyrimidine derivatives
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CR20160553A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
NZ732799A (en) Picolinamides with fungicidal activity
CL2016002971A1 (es) Combinación.
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
TWD170352S (zh) 項鍊
EA201790785A1 (ru) Производные тетрагидроизохинолина
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EP3559253A4 (en) BLOOD PROFILING WITH PROTEASE INHIBITORS
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
EA201790526A1 (ru) Фармацевтические комбинации ситаглиптина
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
TWD177392S (zh) 飾品
UA95303U (xx) Ферментний препарат "проторизин"
TWD173435S (zh) 土除
TH1601001559A (th) สารเชิงซ้อนที่มีโอลิโกนิวคลีโอไทด์ที่มีแอคทิวิตีการเสริมฤทธิ์ทางอิมมูน และการใช้ของมัน
AU356752S (en) Point of sale unit
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin
UA94728U (uk) Магнітокерований сорбент для очищення біологічних рідин від комплексів цитостатиків
TWD169396S (zh) 手鍊

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ